All In Biotech

Drug Trial Radar · NCT00756509

Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib

An Open-label, Multi-center, Single-arm Study to Evaluate the Efficacy of Nilotinib in Adult Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line Treatment

Last checked: Nov 20, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

34

Actual

Start

Aug 29, 2008

Primary completion

Dec 18, 2024

Study completion Dec 18, 2024

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Sep 22, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this multicenter, single-arm, phase II trial is to evaluate the efficacy of Nilotinib in patients with unresectable or metastatic gastrointestinal stromal tumors (GIST).

Conditions

  • Gastrointestinal Stromal Tumors

Interventions

  • NilotinibDrug

    800 mg/d orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Participants With Best Overall Response at Month 6 (Core Phase) Determined According to the RECIST v1.0.Time frame: from baseline to month 6, core phase

Locations

10 sites in 5 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Helsinki, Finland

  • Novartis Investigative Site

    Lyon, France

  • Novartis Investigative Site

    Bad Saarow, Germany

  • Novartis Investigative Site

    Essen, Germany

  • Novartis Investigative Site

    Hanover, Germany

  • Novartis Investigative Site

    Munich, Bavaria, Germany

  • Novartis Investigative Site

    Milan, MI, Italy

  • Novartis Investigative Site

    Palma, Balearic Islands, Spain

  • Novartis Investigative Site

    L'Hospitalet de Llobregat, Barcelona, Spain

  • Novartis Investigative Site

    Valencia, Valencia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.